In what’s being hailed as the most significant coronaviral pandemic to hit the United States, the National Institutes of Health is deploying a new vaccination campaign that will test thousands of thousands of people for the new coronavivirus.
The goal is to test as many people as possible for COVID-19 by 2020, and to see how effective the new vaccine is at slowing the spread of the virus.
But the government has set up a number of new challenges to ensure that testing goes smoothly.
Here are some of the challenges facing the National Institute of Allergy and Infectious Diseases (NIAID) as it works to deploy a new vaccine.
The most significant of these challenges is the amount of time it takes to conduct the testing.
The first phase of testing is slated to begin on July 7.
The new coronivirus vaccine will need to be tested for the first time on August 10.
This is a big problem.
It’s the one that we have the longest testing timeline in the country, so we need to get the vaccine out as soon as we can.
And the more time we delay the more problems we have and we will have in the next two to three years.
And we need as much time as we have to get out as much vaccine as possible.
The National Institute for Allergy, Infectious Disease and Respiratory Diseases has also set up additional challenges, including getting samples from patients who tested positive for COID-19 before the start of the pandemic.
These tests are going to take about two weeks, so they need to come out and test for COIDs and they need it out as fast as we possibly can, Dr. Paul Fauci, who leads NIAID’s COVID vaccine project, told NBC News.
The second phase of the testing will begin in mid-September and will take about three weeks.
The vaccine needs to be available for testing for about six months before that.
Once the vaccine is out, we’re going to need to work very hard to get it tested for other viruses.
And once we get the test results back, we’ll see how many people have been exposed and we can make recommendations to the vaccine manufacturers to make sure they have a high enough level of the vaccine to ensure people are protected from other infections, Dr Fauccia said.
To be clear, NIAIDS doesn’t want to send the coroniviruses to people who have never had COID before.
And if the vaccine doesn’t work for someone who has had COIDs before, then they don’t need to take it.
So it will take the vaccine from the patients that have had the virus and make recommendations based on the risk of exposure.
Dr. Faucci also said that this will be the first test to be conducted with the new COVID vaccines in the United Kingdom, which will be launched in 2020.